Treating Myelodysplastic Syndrome by Downregulating the RAS Pathway with Dr. Steven Fruchtman Onconova Therapeutics TRANSCRIPT
Manage episode 267708219 series 99915
Steven M. Fruchtman, M.D., President and Chief Executive Officer, Onconova Therapeutics discusses Rigosertib, a drug that has the potential to downregulate the RAS pathway, the most commonly mutated gene in cancer. Rigosertib is a proprietary phase 3 small molecule, currently being evaluated in second-line treatment of patients with higher-risk myelodysplastic syndrome (MDS) and refractory higher-risk MDS patients. Also known as pre-leukemia, MDS is a cancer of the bone marrow stem cell and the mission of Onconova is to prolong the lives of those suffering from this disease.
#cancer #oncology #RAS #MDS #PreLeukemia #Leukemia $ONTX